LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

LLY

1,070.14

+0.01%↑

JNJ

205.37

-1.16%↓

ABBV

228.73

+0.59%↑

UNH

324.38

+0.04%↑

AZN

91.96

+0.51%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

594.68 -0.87

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

590.54

Max

609.61

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
EPS	-4.956
Winstmarge	-39.75
Werknemers	528
EBITDA	-75M -114M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+1.94% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.5B 13B
Vorige openingsprijs	595.55
Vorige sluitingsprijs	594.68

Nieuwssentiment

By Acuity

40%

60%

140 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 dec 2025, 23:54 UTC

Belangrijke Marktbewegers

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dec 2025, 19:08 UTC

Acquisities, Fusies, Overnames

Correction to Alphabet to Buy Intersect Article

22 dec 2025, 17:21 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dec 2025, 16:46 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dec 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dec 2025, 23:42 UTC

Marktinformatie

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dec 2025, 22:30 UTC

Winsten

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 21:37 UTC

Acquisities, Fusies, Overnames

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dec 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dec 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dec 2025, 20:52 UTC

Acquisities, Fusies, Overnames

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dec 2025, 20:09 UTC

Marktinformatie

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dec 2025, 19:56 UTC

Marktinformatie

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dec 2025, 19:49 UTC

Acquisities, Fusies, Overnames

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dec 2025, 19:23 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dec 2025, 19:23 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Global Energy Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Precious Metals Climb to New Heights -- Market Talk

22 dec 2025, 18:45 UTC

Marktinformatie

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dec 2025, 18:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dec 2025, 18:23 UTC

Acquisities, Fusies, Overnames

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dec 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

22 dec 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

1.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 614.5 USD 1.94%

Hoogste 900 USD

Laagste 523 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

140 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.